| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PCK2; PEPCK2; Phosphoenolpyruvate carboxykinase [GTP]; mitochondrial; PEPCK-M; Phosphoenolpyruvate carboxylase |
| Entrez GeneID | 5106 |
| WB Predicted band size | Calculated MW: 71 kDa; Observed MW: 71 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human PCK2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下为示例性参考文献(具体文献需根据实际研究查询)：
1. **"Mitochondrial phosphoen醇丙酮酸羧激ase (PCK2) regulates cancer cell proliferation through metabolic reprogramming"**
- 作者：Liu Y, et al.
- 摘要：研究通过开发特异性PCK2抗体，验证其在肝癌细胞中的线粒体定位，并发现PCK2通过调控谷氨酰胺代谢促进肿瘤生长。
2. **"Characterization of a novel monoclonal antibody against human PCK2 for metabolic studies"**
- 作者：Smith J, et al.
- 摘要：报道一种高特异性PCK2单克隆抗体的制备与验证，应用于Western blot和免疫组化，揭示PCK2在糖尿病模型中的表达变化。
3. **"PCK2-mediated gluconeogenesis drives chemoresistance in colorectal cancer"**
- 作者：Chen R, et al.
- 摘要：利用PCK2抗体及基因敲除技术，证明PCK2通过增强糖异生途径导致结直肠癌细胞对化疗药物的抵抗。
4. **"Tissue-specific expression profiling of PEPCK isoforms using isoform-selective antibodies"**
- 作者：Gomez A, et al.
- 摘要：对比PCK1(胞质型)和PCK2(线粒体型)抗体在多种组织中的检测效果，揭示PCK2在心脏和肾脏中的独特代谢功能。
注：以上为模拟示例，实际文献需通过PubMed或Google Scholar以“PCK2 antibody”“PEPCK2”等关键词检索。
The PCK2 antibody targets phosphoenolpyruvate carboxykinase 2 (PCK2), a mitochondrial enzyme critical in gluconeogenesis and energy metabolism. PCK2 catalyzes the conversion of oxaloacetate to phosphoenolpyruvate, a rate-limiting step that regulates glucose synthesis and cataplerosis. Unlike cytosolic PCK1. PCK2 is localized to mitochondria and plays a dual role in maintaining metabolic homeostasis by balancing glucose production and tricarboxylic acid (TCA) cycle intermediates. It is highly expressed in gluconeogenic tissues (e.g., liver, kidney) and cancers, where it supports tumor growth under nutrient stress by fueling anabolic pathways.
PCK2 antibodies are widely used to study metabolic disorders (e.g., diabetes, obesity) and cancer biology. They enable detection of PCK2 protein expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Research has linked PCK2 upregulation to hepatocellular carcinoma, breast cancer, and glioblastoma, highlighting its role in promoting cell survival via adaptive metabolism. Antibody specificity is validated against recombinant PCK2 or knockout models, with attention to its ~70 kDa molecular weight and mitochondrial localization. These tools help unravel PCK2's regulatory mechanisms, including post-translational modifications and interactions with metabolic signaling pathways (e.g., mTOR, AMPK). Ongoing studies explore PCK2 inhibition as a therapeutic strategy for metabolic diseases and oncology.
×
